Pfizer ED claim is sound, ASA rules

Acomplaint challenging a claim made by Pfizer in an advertisement for its Viagra Connect erectile dysfunction (ED) drug that “4.3 million men in the UK experience erectile problems” has not been upheld by the UK Advertising Standards Authority (ASA).

Acomplaint challenging a claim made by Pfizer in an advertisement for its Viagra Connect erectile dysfunction (ED) drug that “4.3 million men in the UK experience erectile problems” has not been upheld by the UK Advertising Standards Authority (ASA).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

Alfasigma Seeking Slice Of EU’s Largest OTC Market With German Launch

 
• By 

Italy's Alfasigma has expanded its operation in Germany with the creation of a new Consumer Healthcare unit. Led by Rüdiger Hoppe, the business is rolling out OTC medical devices and dietary supplements in the gastrointestinal category.

Maxwellia Launches UK TV Campaign For Evana Showing Reality Of Menstruation

 
• By 

Maxwellia's “bold, honest, and completely unfiltered” campaign for Evana menstrual health brand tells the story of a woman dealing with the realities of a heavy period, showing “real blood, real leaks.”

Haleon Launches ‘Prescription Strength’ Hayfever Remedy In The UK

 
• By 

Pirilieve Hayfever Relief Tablets contain 120mg fexofenadine hydrochloride, which the firm notes is an active ingredient that was “previously only available behind pharmacy counters.”

Haleon’s US Eroxon Launch Falls Short Of Expectations

 
• By 

Consumer uptake of Eroxon - the first FDA-approved OTC ED treatment available in the US - has been slower than expected, according to Haleon, which says its working with retailers to build awareness.

More from Business

KKR Expands Health & Beauty Portfolio With Deal For Sweden’s Karo

 
• By 

Consumer health player Karo is changing hands from EQT to KKR in a deal thought to value the Stockholm-based firm at over €2.5bn.

‘The Only Certainty Is Uncertainty’ In The UK’s Consumer Health Market

 
• By 

While uncertainty might reign in the UK consumer health market - which grew by by 8% to £4.1bn ($5.3bn) in 2024 - “opportunity is everywhere” according to NielsenIQ health and beauty insights manager Alex Heffernan.

France’s Boiron Looks To Future After Challenging Year

 
• By 

The homeopathy specialist reported a big decline in profits in 2024 as a move to restructure its ailing French operation hit the bottom line.